## Immunogenicity of SARS-CoV-2 Vaccine in Dialysis

Authors: Eduardo Lacson, Jr., M.D.,M.P.H.,<sup>1,2</sup> Christos P. Argyropoulos, M.D.,<sup>3</sup> Harold J. Manley, PharmD,<sup>2</sup> Gideon Aweh, M.S.,<sup>2</sup> Andrew I. Chin, M.D.,<sup>4</sup> Loay H. Salman, M.D., M.B.A,,<sup>5</sup> Caroline M. Hsu, M.D.,<sup>1</sup> Doug S. Johnson, M.D.,<sup>2</sup> Daniel E. Weiner M.D.<sup>1</sup>

#### Institutions:

<sup>1</sup> Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

<sup>2</sup> Dialysis Clinic, Inc., Nashville, Tennessee

<sup>3</sup> Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, New

Mexico

<sup>4</sup> Division of Nephrology, University of California, Davis School of Medicine, Sacramento,

California

<sup>5</sup> Division of Nephrology, Albany Medical College, Albany, New York

Word Count: 1,197

**Abstract Word Count**: 250

### **Key Words:**

Dialysis, End Stage Kidney Disease, Chronic Kidney Disease, SARS-CoV-2, COVID-19, Immunization, Vaccine/Vaccination

**COI Statement**: EL, HJM, GA, DSJ are employees of Dialysis Clinic, Inc. DEW receives funding paid to his institution for his role as Medical Director of Clinical Research for DCI. CPA, AIC, LHS, DEW are medical directors of DCI facilities.

Funding Source: No external funding.

## Significance:

In this retrospective observational evaluation of SARS-CoV-2 mRNA vaccine response defined by detectable levels of immunoglobulin-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike antigen of ≥2 in serum of patients receiving maintenance dialysis, 165/186 (88.7%) were found to be seropositive (with 70% at maximum titer) at least 14 days after completing the second dose. No significant differences were observed by race or other subgroup or by vaccine manufacturer. Therefore, an equitable and aggressive vaccination strategy for all eligible maintenance dialysis patients, regardless of age, sex, race, ethnicity, or disability, is warranted to prevent the extremely high morbidity and mortality associated with COVID-19 in this high risk population.

**Abstract** 

Background: Patients receiving maintenance dialysis represent a high risk, immune-

compromised population with 15-25% COVID mortality rate who were unrepresented in clinical

trials evaluated for mRNA vaccines' emergency use authorization.

Method: All patients receiving maintenance dialysis that received two doses of SARS-CoV-2

mRNA vaccines with antibody test results drawn ≥14 days after the second dose, as documented

in the electronic health record through March 18, 2021 were included. We report seroresponse

based on levels of immunoglobulin-G against the receptor binding domain of the S1 subunit of

SARS-CoV-2 spike antigen (seropositive ≥2) using FDA-approved semi-quantitative

chemiluminescent assay (ADVIA Centaur® XP/XPT COV2G).

Results: Among 186 dialysis patients from 32 clinics in 8 states tested 23±8 days after receiving

2 vaccine doses, mean age was 68±12 years, with 47% women, 21% Black, 26% residents in

long-term care facilities and 97% undergoing in-center hemodialysis. Overall seropositive rate

was 165/186 (88.7%) with 70% at maximum titer and with no significant difference in seropositivity

between BNT162b2/Pfizer (N=148) and mRNA-1273/Moderna (N=18) vaccines (88.1% vs.

94.4%, p=0.42). Among patients with COVID-19 history, seropositive rate was 38/38 (100%) with

97% at maximum titer.

Conclusion: Most patients receiving maintenance dialysis were seropositive after two doses of

BNT162b2/Pfizer or mRNA-1273/Moderna vaccine. Early evidence suggests that vaccinated

dialysis patients with prior COVID-19 develop robust antibody response. These results support

an equitable and aggressive vaccination strategy for eligible dialysis patients, regardless of age,

sex, race, ethnicity, or disability, to prevent the extremely high morbidity and mortality associated

3

with COVID-19 in this high risk population.

Nearly 550,000 people in the United States (US) receive maintenance dialysis and prevalence estimates approach 3 million worldwide. 1.2 Patients receiving maintenance dialysis (henceforth "dialysis patients"), particularly those receiving hemodialysis, comprise a population of vulnerable individuals who cannot self-isolate, have a high incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and have Coronavirus Disease 2019 (COVID-19)-associated mortality of 15 to 25%, 3-5 making effective vaccination a priority. Despite this heightened risk and prior reports of diminished response to vaccines versus other viruses such as hepatitis-B and influenza, 6-8 the immune response to SARS-CoV-2 vaccination among dialysis patients is unknown due to insufficient trial data. Accordingly, we performed a quality improvement evaluation of multiple Dialysis Clinic, Inc. (DCI) dialysis clinics in the US assessing antibody response following administration of SARS-CoV-2 messenger RNA (mRNA) vaccines.

#### Methods

#### Study Setting

DCI implemented a standard clinical protocol for systematic measurement of SARS-CoV-2 spike-antibody immunoglobulin-G (SAb-IgG) that physicians could activate for vaccination in the outpatient dialysis clinic, similar to that for hepatitis-B post-vaccination testing.<sup>6</sup> As access to the SARS-CoV-2 mRNA vaccines for dialysis patients varied among and within states, they were obtained from nursing homes, hospitals, locally designated centers and pharmacies, and only in few dialysis clinics. Individual physicians ordered post-vaccination SAb-IgG titers based on patient accessibility and clinical interest. All vaccinations were verified and recorded in the DCI electronic health record (EHR). This interim report includes a retrospective evaluation of all patients receiving 2 doses of either BNT162b2/Pfizer or mRNA-1273/Moderna vaccine per manufacturer's recommendation across 32 DCI clinics in 8 states with SAb-IgG measured ≥14 days after the second dose, documented as of March 18, 2021.

SARS-CoV-2 Spike Antibody Assay

DCI Lab measured SAb-IgG against the receptor binding domain (RBD) of the S1 subunit of

SARS-CoV-2 spike antigen using US-FDA-approved chemiluminescent assay (ADVIA Centaur®

XP/XPT COV2G). 9, 10 This semi-quantitative assay has a range between 0 and ≥20, with a positive

threshold of ≥2. S1-RBD-antibodies are relevant to vaccines incorporating this immune-dominant

region to elicit neutralizing (and therefore likely protective) antibodies in vaccinated individuals. 11

Electronic Health Record

Vaccination dates, SAb-IgG results, demographic and clinical data including age, sex,

race/ethnicity, body mass index, dialysis parameters (i.e. vintage, modality, access, adequacy),

albumin, number and types of comorbidities, use of immunomodulatory agents, history of

transplantation or COVID-19 diagnosis, and other vaccines administered or hospitalization within

14 days of vaccination were obtained from the DCI-EHR. This retrospective evaluation is a DCI

quality improvement evaluation under Western Institutional Review Board (WIRB) exemption.

Statistical analyses were performed using SAS v9.4.

Results

Among 186 dialysis patients receiving 2 doses of vaccine, mean age was 68±12 years, with 47%

women, 21% Black, 26% residents in long-term care facilities and 97% undergoing in-center

hemodialysis (**Table 1**). SAb-IgG was positive (≥2) in 165/186 (88.7%) with no significant

difference between BNT162b2/Pfizer (N=148) and mRNA-1273/Moderna (N=18) vaccines

(88.1% vs. 94.4%, p=0.42). The distribution of titer levels drawn over 23±8 days after the 2<sup>nd</sup> dose

is shown in Figure 1. Non-responders had mean SAb-IgG titer of 0.4±0.2 vs. 18.2±4.3 among

5

responders (p<0.0001).

Among 148 patients without known COVID-19, 127 (85.8%) were seropositive following

vaccination. All 38 patients with COVID-19 diagnosis were seropositive, irrespective of vaccine

type, with 37/38 at maximum limit of the assay. In 36 patients, COVID-19 diagnosis occurred

181±118 days prior to completing vaccination. The remaining two patients were long-term care

facility residents each exposed to a roommate, and were tested while asymptomatic at 1 and 5

days after their second vaccine dose, respectively (with SAb-IgG titers obtained 20 days and 23

days after vaccination, respectively). Upon review, the latter patient had recent gastrointestinal

upset and constipation but neither was hospitalized.

Seroresponse occurred in 73 of 88 women versus 92 of 98 men (83% vs. 94%, p=0.02). Results

of univariate analysis are indicated in **Table 1**. Non-responders were newer to dialysis and more

likely to have other vaccines administered or be hospitalized within 14 days of SARS-CoV-2

vaccination, have potential immunosuppressed state related to immune-modulating drugs, prior

transplant, and/or immune-deficiency disorders, and congestive heart failure (CHF). A summary

of the clinical characteristics of non-responders is provided in **Table 2**.

**Discussion** 

Among maintenance dialysis patients in the US, 88.7% achieved SAb-IgG >2, measured ≥14

days after two doses of SARS-CoV-2 mRNA vaccine. Near universal seroconversion rates

occurred in clinical trials utilized for these vaccines' emergency use authorization, but notably did

not include patients on dialysis. Lower seroconversion rate was not unexpected, given the

widespread immune dysfunction observed in dialysis-dependent patients. These immune

alterations included skewed Th1/Th2 responses, impaired function of the professional antigen

presenting cells (APC), and susceptibility of B-cells to apoptosis. 12 The combined deficits in T-

cell, APC and B-cell functions render dialysis patients less likely to both seroconvert and maintain

protective titers over time compared to individuals without kidney disease, 13 previously observed

with pneumococcal, hepatitis-B and H1N1 influenza vaccines. 7,8,14

Factors associated with poor seroconversion in our cohort include female sex, younger vintage,

potential immunosuppression from diseases, transplant or medications, CHF and co-vaccination

and hospitalization during the peri-vaccination period. A recent meta-analysis suggests women

receiving dialysis respond to vaccines equally to men, although differences in seroconversion

rates by sex were noted in some hepatitis-B series.7 However, we caution that some of these

associations, including that for women, may not be sustained as we accumulate more data. Of

note, potential immunosuppressed states and acute hospitalization during the vaccine series have

face validity to impact immune response, particularly in the setting of uremic inflammation. <sup>7,12,15</sup>

Considering the devastating impact of COVID-19 on dialysis patients compared to the potentially

dramatic benefit of vaccination on severity of illness,3-5 it is imperative to explore strategies to

monitor and maximize seroconversion. Such knowledge may be useful for patient education and

dialogue to reinforce preventive measures. Strategies to improve seroconversion may include

additional or higher vaccine doses. Monitoring longitudinal SAb-IgG could inform potential use of

booster doses, similar to algorithms used for hepatitis-B vaccination. Such tracking is a

component of the quality program at DCI and will be critical in informing the development of

alternative vaccination regimens.

A strength of the current report is coverage of multiple areas of the country with a diverse dialysis

population. Although limited by small sample size, the data appear sufficient to emphasize that

seroconversion should be expected for the majority of maintenance dialysis patients. Additional

limitations include an observational design that may have led to residual confounding and

selection biases, heavily influenced by accessibility and availability of vaccines. Future studies

could also evaluate T-cell responses given that specific clinical implications of serology tests including the SAb-IgG we utilized, need further elucidation.

In conclusion, the vast majority of maintenance dialysis patients responded with IgG spike antibody titers to a complete series of both SARS-CoV-2 mRNA BNT162b2 and mRNA-1273 vaccines. Further study is needed to determine duration of the seroprotection as well as the ideal approach to non-responders, including whether they should receive a booster dose. Early evidence suggests that vaccinated dialysis patients with prior COVID-19 develop robust antibody response. Our findings support an equitable and aggressive vaccination strategy for all eligible maintenance dialysis patients regardless of age, sex, race, ethnicity, or disability, to prevent the extremely high morbidity and mortality associated with COVID-19 in this high risk population.

Acknowledgment: We are grateful for the assistance from DCI Medical Directors and Clinic Managers caring for our patients who worked to have our patients vaccinated against SARS-CoV-2 and tirelessly documented the information in the EHR. We further thank the nephrologists who have implemented DCI clinical and quality improvement protocols and care recommendations, including the SARS-CoV-2 seroresponse testing algorithm. We also thank Beth Kammer from DCI Laboratories, Vlad Ladik and Brian Tinger from DCI IT-Analytics Department, Karen Majchrzak with DCI Research and Senior/Area Operations Directors who supported this quality improvement project. Dr. Hsu is funded by T32-DK007777.

## References:

- 1. Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. Feb 29 2020;395(10225):709-733.
- United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
- 3. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 Infection Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. *American Journal of kidney diseases: the official journal of the National Kidney Foundation.* Jan 16 2021.
- 4. Sim JJ, Huang CW, Selevan DC, Chung J, Rutkowski MP, Zhou H. COVID-19 and Survival in Maintenance Dialysis. *Kidney Med.* Jan-Feb 2021;3(1):132-135.
- 5. Couchoud C, Bayer F, Ayav C, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. *Kidney international.* Dec 2020;98(6):1519-1529.
- 6. Chi, C, Patel, P, Pilishvilli T, et al. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. CDC; December, 2012:1-12 <u>Updated Vaccine</u> <u>Guideline for Dialysis and Chronic Kidney Disease Patients (cdc.gov)</u> Last Accessed March 26, 2021.
- 7. Udomkarnjananun S, Takkavatakarn K, Praditpornsilpa K, et al. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. *Journal of Nephrology*. Apr 2020;33(2):343-354.
- 8. Crespo M, Collado S, Mir M, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. *Clinical Journal of the American Society of Nephrology:* Sep 2011;6(9):2208-2214.
- 9. <a href="https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov-2-igg-assay">https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov-2-igg-assay</a> Manufacturer website accessed March 22, 2021.
- 10. <a href="https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas">https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas</a> FDA website accessed March 22, 2021.
- 11. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 586, 589–593 (2020).
- 12. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clinical Journal of the American Society of Nephrology: Sep 2008;3(5):1526-33.
- 13. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. American Journal of Kidney Diseases: 2005 Dec;46(6):997-1011.
- 14. Vandecasteele SJ, De Bacquer D, Caluwe R, et al. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study. Clin Microbiol Infect. 2018 Jan;24(1):65-71.
- 15. Bergström J, Lindholm B, Lacson E Jr, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial. 2000 May-Jun;13(3):163-75.

# **Figure Legend**

**Figure 1.** Distribution of spike antibody IgG titers for SARS-CoV-2 mRNA vaccinated maintenance dialysis patients (N=186) drawn over 23±8 days after the second dose.

**Table 1**. Patient characteristics presented as mean ± standard deviation or number (percent).

Demographics	All Patients	Responders	Non-Responders	
	(N=186)	(N=165)	(N=21)	
Age (years)	67.9 ± 12.2	67.7 ± 12.4	70.0 ± 10.7	
≥ 65 years	123 (66.1)	107 (64.8)	16 (76.2)	
Female	88 (47.3)	73 (44.2)	15 (71.4) <sup>a</sup>	
Race				
White	73 (39.3)	62 (37.6)	11 (52.4)	
Black	39 (21.0)	36 (21.8)	3 (14.3)	
Native American	33 (17.7)	31 (18.8)	2 (9.5)	
Asian/Pacific Islander	19 (10.2)	18 (10.9)	1 (4.8)	
Other/Unknown	22 (11.8)	18 (10.9)	4 (19.1)	
Hispanic	15 (8.1)	14 (8.5)	1 (4.8)	
Vintage (months)	58.1 ± 54.3	60.6 ± 54.2	38.7 ± 52.2 ª	
Body Mass Index (kg/m²)	28.7 ± 7.1	28.7 ± 6.9	29.2 ± 8.8	
Long Term Care Facility	48 (25.8)	41 (24.9)	7 (33.3)	
Home Dialysis	6 (3.2)	5 (3.0)	1 (4.8)	
Dialysis Access				
Fistula	129 (69.4)	117 (70.9)	12 (60.0)	
Graft	29 (15.6)	26 (15.8)	3 (15.0)	
Central Venous Catheter	23 (12.4)	18 (10.9)	5 (25.0)	
Peritoneal Dialysis Catheter	5 (2.7)	4 (2.4)	1 (4.8)	
Adequate Dialysis Dose <sup>c</sup>	174 (93.6)	155 (93.9)	19 (90.5)	
Serum Albumin (g/dl)	3.8 ± 0.4	3.8 ± 0.4	3.5 ± 0.6	

		T	
Other Vaccines within 14 days	20 (10.8)	15 (9.1)	5 (23.8) <sup>a</sup>
Pneumonia	4 (2.2)	3 (1.8)	1 (4.8)
Hepatitis B	17 (9.1)	13 (7.9)	4 (19.1)
Potential Immunosuppression	30 (18.2)	30 (18.2)	8 (38.1) <sup>a</sup>
Immune-modulating Meds	29 (15.6)	23 (13.9)	6 (28.6)
Prior Transplant	10 (5.4)	8 (4.9)	2 (9.5)
Immunodeficiency Disorder	10 (5.4)	6 (3.6)	4 (19.1)
Hospitalization within 14 days	34 (18.3)	24 (14.6)	10 (47.6) <sup>b</sup>
Disability <sup>d</sup>	17 (9.1)	17 (10.3)	0 (0.0)
Tobacco Use	22 (11.8)	21 (12.7)	1 (4.8)
Alcohol Abuse Disorder	14 (7.5)	14 (8.5)	0 (0.0)
Drug Abuse Disorder	8 (4.3)	6 (3.6)	2 (9.5)
COVID-19 History	38 (20.4)	38 (23.0)	0 (0.0) <sup>a</sup>
Number of Comorbidities	3.2 ± 1.9	3.2 ± 1.9	3.6 ± 1.7
Diabetes Mellitus	129 (69.4)	113 (68.5)	16 (76.2)
Hypertension	152 (81.7)	134 (81.2)	18 (85.7)
Congestive Heart Failure	37 (19.9)	27 (16.4)	10 (47.6) <sup>b</sup>
COPD <sup>e</sup>	34 (18.3)	30 (18.2)	4 (19.1)
Stroke/Cerebrovascular Disorder	23 (12.4)	19 (11.5)	4 (19.1)
Peripheral Vascular Disease	25 (13.4)	22 (13.3)	3 (14.3)
Thyroid Disorder	36 (19.4)	30(18.2)	6 (28.6)
History of Cancer	18 (9.7)	14 (8.5)	4 (19.1)

<sup>&</sup>lt;sup>a</sup> P-value <0.05; <sup>b</sup> P-value <0.01; <sup>c</sup> Adequate dialysis defined by hemodialysis dose spKt/V≥1.2 or peritoneal dialysis dose weekly Kt/V≥1.7; <sup>d</sup> Amputee, wheelchair use or inability to perform activities of daily living; <sup>e</sup> COPD=Chronic Obstructive Pulmonary Disease. Note: Comparisons between responders with non-responders utilized Chi-Square or Analysis of Variance for categorical variables and T-test / Kruskal-Wallis/Mann-Whitney test for normal/non-normally distributed continuous variables.

Table 2. Detailed summary of characteristics of SARS-CoV-2 mRNA vaccine non-responders.

			Race	Ethnicity	Notable Comorbidity	Prescribed Medications Impacting Immune Function	Clinical Event within 14 days of COVID Vaccination	
	Age							
	Range	Sex					Hospitalization	Other Vaccine
			Native	<b>N</b> T				
1	65-69	F	America n	Non- Hispanic	DM	None	Yes	Heplisav
1	03-07	1	11	Trispanic	DM, seizure	TVOILC	1 03	Пернзач
			Native		disorder, CVA,			
			America	Non-	PVD, Depression			
2	65-69	F	n	Hispanic	calciphylaxis	None	None	None
				1	DM, A fib, CHF,			
3	80-84	F	White	Hispanic	hypothyroid	None	Yes	None
				1	DM, A fib, CHF,			
			Unknow	Non-	hypothyroid,			
4	80-84	M	n	Hispanic	COPD	None	Yes	None
					SLE, prior			
				Non-	Transplant, SVC	hydroxychloroquine,		
5	75-79	F	Black	Hispanic	syndrome	prednisone	None	None
					Thyrotoxicosis,			
				Non-	Bipolar Disorder,			
6	55-59	F	White	Hispanic	Depression	None	None	None
					HIV, Bipolar			
					Disorder, Illicit			
				NT.	drug use,	lamivudine,		
7	50.54	E	3371 .7	Non-	Cervical CA	dolutegravir,	NT.	N
7	50-54	F	White	Hispanic	history	ritonavir, darunavir	None	None
				Non-	DM, Gout, Osteoarthritis,	prednisone,		
8	70-74	F	White	Hispanic	prior Transplant	tacrolimus	None	Engerix
0	70-74	1	Willie	Trispanic	CHF, SLE,	tacionnus	None	Eligerix
					Hepatitis B,	prednisone,		
					Osteoarthritis,	mycophenolate,		
				Non-	Colon CA	hydroxychloroquine,		
9	70-74	F	Asian	Hispanic	history	entecavir	None	None
				1	DM, CHF,			
					Hepatitis B,			
10	45-49	F	Black	Unknown	PVD,	None	Yes	None
						prednisone,		
						tacrolimus,		
			Unknow		DM, GERD,	mycophenolate,		
11	70-74	M	n	Unknown	prior Transplant	thymoglobulin <sup>c</sup>	Yes	Prevnar
1.20	70.74	, .	****	Non-	DM, A fib,	)		
12ª	70-74	M	White	Hispanic	Depression	None	None	None
12	50.54	E	<b>1371</b> '4	Non-	DM, CHF,	N.	NI.	NI-
13	50-54	F	White	Hispanic	hypothyroid	None	None	None
				Non-	DM, CHF, CAD, hypothyroid,			
14	80-84	F	White	Non- Hispanic	Gout, Depression	None	Yes	None
14	00-04	Г	VV IIILE	Trispanic	Jour, Depression	None	1 68	None

					DM, Depression,			
1.5	70.74	F	3371-14-	T I1	_	N	V	Nama
15	70-74	Г	White	Unknown	COPD	None	Yes	None
					DM, CHF, Lyme			
					disease,			
					Depression,			
					Osteoarthritis,			
			Unknow		Gout, Uterine			
16	65-69	F	n	Unknown	CA history	None	None	None
					DM, CHF, DVT,			
				Non-	BPH, GERD,			
17 <sup>b</sup>	75-79	M	Black	Hispanic	Gout	None	Yes	Heplisav
			Unknow	Non-				
18	65-69	F	n	Hispanic	DM	None	Yes	None
					DM,			
					hypothyroid,			
					gout,			
					neuropathy,			
				Non-	Melanoma CA			
19	75-79	M	White	Hispanic	history,	None	Yes	Heplisav
				Non-	DM, A fib, CHF,			
20	80-84	M	White	Hispanic	COPD, Gout	hydroxychloroquine	Yes	None
					A fib, CHF,			
					Breast CA			
21	60-64	F	White	Unknown	history	None	Yes	None

<sup>&</sup>lt;sup>a</sup> Received Moderna vaccine, all else received Pfizer vaccine; <sup>b</sup> Peritoneal dialysis modality, all else utilized hemodialysis; <sup>c</sup> Communicated by nephrologist.

Figure 1

